Track ARS Pharmaceuticals Inc. Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

ARS Pharmaceuticals Inc. Common Stock SPRY · Stock Open ARS Pharmaceuticals Inc. Common Stock in new tab

10.48 USD
EPS
-0.50
P/B
5.47
ROE
-22.41
Target Price
26.50 USD
Loading chart...
Key Metrics
Earnings dateMarch 8, 2027
EPS-0.50
Book Value2.07
Price to Book5.47
Debt/Equity0.05
% Insiders23.334%
Estimates
Forward P/E-31.74
Forward EPS-0.76
Target Mean Price26.50

DCF valuation

Model fair value for ARS Pharmaceuticals Inc. Common Stock (SPRY)
Result
Sign in to run the valuation for SPRY.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
mean target 26.50 USD (low 19.00, high 35.00)
Low 19.00
Mean 26.50
High 35.00
Price 10.48
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

ARS Pharmaceuticals Inc. Common Stock Logo ARS Pharmaceuticals Inc. Common Stock Analysis (SPRY)

United States Health Care Official Website Stock

Is ARS Pharmaceuticals Inc. Common Stock a good investment? ARS Pharmaceuticals Inc. Common Stock (SPRY) is currently trading at 10.48 USD. Market analysts have a consensus price target of 26.50 USD. This suggests a potential upside from current levels.

Earnings Schedule: ARS Pharmaceuticals Inc. Common Stock is expected to release its next earnings report on March 8, 2027. The market consensus estimate for Forward EPS is -0.76.

Investor FAQ

Does ARS Pharmaceuticals Inc. Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is ARS Pharmaceuticals Inc. Common Stock?

ARS Pharmaceuticals Inc. Common Stock is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be March 8, 2027. The company currently has a trailing EPS of -0.50.

Company Profile

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

Exchange Ticker
NMS (United States) SBTX
NMS (United States) SPRY
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion